Risk of lymphoproliferative disorders among first-degree relatives of lymphoplasmacytic lymphoma/Waldenström macroglobulinemia patients: A population-based study in Sweden

Blood

Volumn 112, Issue 8, 2008, Pages 3052-3056

  Kristinsson, Sigurdur Y ^a   Björkholm, Magnus ^a   Goldin, Lynn R ^b   McMaster, Mary L ^b   Turesson, Ingemar ^c   Landgren, Ola ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b NATIONAL CANCER INSTITUTE   (United States)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER RISK; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; FEMALE; GENETIC ASSOCIATION; GENETIC RISK; HEREDITY; HODGKIN DISEASE; HUMAN; LYMPHOMA; LYMPHOPLASMACYTIC LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; POPULATION RESEARCH; PRIORITY JOURNAL; RISK ASSESSMENT; SURVIVAL RATE; SWEDEN; WALDENSTROEM MACROGLOBULINEMIA; ADOLESCENT; B CELL LEUKEMIA; CASE CONTROL STUDY; FAMILY HEALTH; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; REGISTER;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; FAMILY HEALTH; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; REGISTRIES; SWEDEN; WALDENSTROM MACROGLOBULINEMIA;

EID: 54049129700     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-06-162768     Document Type: Article

References (41)

1. Owen RG, Treon SP, Al-Katib A, et al. Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol. 2003;30:110-115.
2. Jaffe ES, Harris NL, Stein H, Vardiman JW. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon. France: IARC Press; 2001.
3. Björkholm M. Lymphoplasmacytic Lymphoma/Waldenström's Macroglobulinemia. In: Canellos G, Lister AT, Young B, eds. The Lymphomas, 2d ed. Philadelphia: W.B. Saunders; 2006:374-380.
4. Groves FD, Travis LB, Devesa SS, Ries LA, Fraumeni JF Jr. Waldenstrom's macroglobulinemia: incidence patterns in the United States, 1988-1994. Cancer. 1998;82:1078-1081.
5. Herrinton LJ, Weiss NS. Incidence of Waldenstrom's macroglobulinemia. Blood. 1993;82: 3148-3150.
6. Dimopoulos MA, Panayiotidis P, Moulopoulos LA, Sfikakis P, Dalakas M. Waldenstrom's macroglobulinemia: clinical features, complications, and management. J Clin Oncol. 2000;18:214-226.
7. Schop RF, Kuehl WM, Van Wier SA, et al. Waldenstrom macroglobulinemia neoplastic cells lack immunoglobulin heavy chain locus translocations but have frequent 6q deletions. Blood. 2002;100: 2996-3001.
8. Aoki H, Takishita M, Kosaka M, Saito S. Frequent somatic mutations in D and/or JH segments of Ig gene in Waldenstrom's macroglobulinemia and chronic lymphocytic leukemia (CLL) with Richter's syndrome but not in common GLL. Blood. 1995:85:1913-1919.
9. Wagner SD, Martinelli V, Luzzatto L. Similar patterns of V kappa gene usage but different degrees of somatic mutation in hairy cell leukemia, prolymphocytc leukemia, Waldenstrom's macroglobulinemia, and myeloma. Blood. 1994;83: 3647-3653.
10. Giordano TP, Henderson L, Landgren O, et al. Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus. JAMA. 2007;297:2010-2017.
11. Koshiol J, Gridley G, Engels EA, McMaster ML, Landgren O. Chronic immune stimulation and subsequent Waldenstrom's macroglobulinemia. Arch Intern Med. 2008 (in press).
12. Massari R, Fine JM, Metais R. Waldenstrom's macroglobulinaemia observed in two brothers. Nature. 1962;196:176-178.
13. Altieri A, Bermejo JL, Hemminki K. Familial aggregation of lymphoplasmacytic lymphoma with non-Hodgkin lymphoma and other neoplasms. Leukemia. 2005;19:2342-2343.
14. Blattner WA, Garber JE, Mann DL, et al. Waldenstrom's macroglobulinemia and autoimmune disease in a family. Ann Intern Med. 1980;93:830-832.
15. Fine JM, Lambin P, Massari M, Leroux P. Malignant evolution of asymptomatic monoclonal IgM after seven and fifteen years in two siblings of a patient with Waldenstrom's macroglobulinemia. Acta Med Scand. 1982;211:237-239.
16. Fine JM, Muller JY, Rochu D, et al. Waldenstrom's macroglobulinemia in monozygotic twins. Acta Med Scand. 1986;220:369-373.
17. Getaz EP, Staples WG. Familial Waldenstrom's macroglobulinaemia: a case report. SAfr Med J. 1977;51:891-892.
18. Linet MS, Humphrey RL, Mehl ES, et al. Acasecontrol and family study of Waldenstrom's macroglobulinemia. Leukemia. 1993;7:1363-1369.
19. Ogmundsdottir HM, Johannesson GM, Sveinsdottir S, et al. Familial macroglobulinaemia: hyperactive B-cells but normal natural killer function. Scand J Immunol. 1994;40:195-200.
20. Seligmann M, Danon F, Mihaesco C, Fudenberg HH. Immunoglobulin abnormalities in families of patients with Waldenstrom's macroglobulinemia. Am J Med. 1967;43:66-83.
21. Taleb N, Tohme A, Abi Jirgiss D, Kattan J, Salloum E. Familial macroglobulinemia in a Lebanese family with two sisters presenting Waldenstrom's disease. Acta Oncol. 1991;30:703-705.
22. Treon SP, Hunter ZR, Aggarwal A, et al. Characterization of familial Waldenstrom's macroglobulinemia. Ann Oncol. 2006;17:488-494.
23. Youinou P, le Goff P. Saleun JP, etal. Familial occurrence of monoclonal gammapathies. Biomedicine. 1978;28:226-232.
24. Socialstyrelsen. Cancer Incidence in Sweden 2006. Stockholm, Sweden: Centre for Epidemiology; 2007.
25. Turesson I, Linet MS, Bjorkholm M, et al. Ascertainment and diagnostic accuracy for hematopoietic lymphoproliferative malignancies in Sweden 1964-2003. Int J Cancer. 2007;121:2260-2266.
26. Skarle A. Flergenerationsregistret. Stockholm, Sweden: Statistics Sweden, Population Statistics; 2001.
27. Liang KY. Estimating effects of probands' characteristics on familial risk: I. Adjustment for censoring and correlated ages at onset. Genet Epidemiol. 1991;8:329-338.
28. Pfeiffer RM, Goldin LR, Chatterjee N, et al. Methods for testing familial aggregation of diseases in population-based samples: application to Hodgkin lymphoma in Swedish registry data. Ann Hum Genet. 2004;68:498-508.
29. Landgren O, Bjorkholm M, Montgomery SM, et al. Personal and family history of autoimmune diabetes mellitus and susceptibility to young-adult-onset Hodgkin lymphoma. Int J Gancer. 2005.
30. Goldin LR, Pfeiffer RM, Gridley G, et al. Familial aggregation of Hodgkin lymphoma and related tumors. Cancer. 2004;100:1902-1908.
31. Jamroziak K, Balcerczak E, Smolewski P, et al. MDR1 (ABCB1) gene polymorphism C3435T is associated with P-glycoprotein activity in B-cell chronic lymphocytic leukemia. Pharmacol Rep. 2006;58:720-728.
32. Rudd MF, Sellick GS, Webb EL, Catovsky D, Houlston RS. Variants in the ATM-BRCA2-CH EK2 axis predispose to chronic lymphocytic leukemia. Blood. 2006;108:638-644.
33. Hohaus S, Massini G, D'Alo F, et al. Association between glutathione S-transferase genotypes and Hodgkin's lymphoma risk and prognosis. Clin Cancer Res. 2003;9:3435-3440.
34. Purdue MP, Lan Q, Kricker A, et al. Polymorphisms in immune function genes and risk of non-Hodgkin lymphoma: findings from the New South Wales non-Hodgkin Lymphoma Study. Carcinogenesis. 2007;28:704-712.
35. Shen M, Zheng T, Lan Q, et al. Polymorphisms in DNA repair genes and risk of non-Hodgkin lymphoma among women in Connecticut. Hum Genet. 2006;119:659-668.
36. Skibola CF, Curry JD, Nieters A. Genetic susceptibility to lymphoma. Haematologica. 2007;92: 960-969.
37. Bakhshi A, Jensen JP, Goldman P, et al. Cloning the chromosomal breakpoint of t(14;18) human lymphomas: clustering around JH on chromosome 14 and near a transcriptional unit on 18. Cell. 1985;41:899-906.
38. Robertson LE, Plunkett W, McConnell K, Keating MJ, McDonnell TJ. Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome. Leukemia. 1996;10:456-459.
39. Steube KG, Jadau A, Teepe D, Drexler HG. Expression of bcl-2 mRNA and protein in leukemialymphoma cell lines. Leukemia. 1995;9:1841-1846.
40. Chng WJ, Schop RF, Price-Troska T, et al. Geneexpression profiling of Waldenstrom macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma. Blood. 2006;108:2755-2763.
41. Smedby KE, Hjalgrim H, Askling J, et al. Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype. J Natl Cancer Inst. 2006;98:51-60.